eszopiclone (lunesta) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor. The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes. Used for the treatment of insomnia.   NCATS

Chemistry

  • SMILES: CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4
  • InChIKey: GBBSUAFBMRNDJC-INIZCTEOSA-N
  • Mol. Mass: 388.808
  • ALogP: 1.57
  • ChEMBL Molecule:
    eszopiclone  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1792 - $15.4437
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-piperazinecarobxylic acid,4-methyl-,(5s)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5h-pyrrolo[3,4-b]pyrazin-5-yl ester | (+)-(5s)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5h-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate | (+)-(5s)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate | esopiclone | estorra | eszopiclone | lunesta | (s)-6-(5-chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5h-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate | (s)-zopiclone

Organizations (57)

Research & Development (40)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Acute Coronary Syndrome (Phase 4)

Anxiety (Phase 4)

Anxiety Disorders (Phase 4)

Arthritis, Rheumatoid (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Depression (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 1)

Fibromyalgia (Phase 4)

Glucose Intolerance (Phase 1)

Healthy Volunteers (Phase 4)

Insulin Resistance (Phase 4)

Marijuana Abuse (Phase 1)

Migraine Disorders (Phase 4)

Parkinson Disease (Phase 3)

Prediabetic State (Phase 1)

Sleep (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Sleep Apnea Syndromes (Phase 2)

Sleep Disorders, Intrinsic (Phase 4)

Sleep Initiation and Maintenance Disorders ()

Sleep Wake Disorders (Phase 4)

Stress Disorders, Post-Traumatic (Phase 4)

Therapeutic Equivalency (Phase 1)

Tobacco Use Disorder (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial Organizations: 40

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue